ALERTO NG PASYENTE: Opsyonal na ngayon ang mga maskara sa aming mga tanggapan ng VOA. Kung ikaw ay immunocompromised o nakakaramdam ng sakit, ang pag-mask ay mahigpit na hinihikayat. Salamat. CLICK HERE para sa karagdagang detalye.​​​​​.

Klinikal na Pananaliksik at Pagsubok

USO 21536

Isang Randomized, Open-label, Phase 3 na Pag-aaral ng Sacituzumab Govitecan at Pembrolizumab Versus Treatment of Physician's Choice at Pembrolizumab sa mga Pasyenteng Nakarati nang Hindi Ginagamot, Locally Advanced, Inoperable, o Metastatic Triple-Negative Breast Cancer, Kaninong Tumor Express PD-L1 (GS- US-592-6173)

 

Mga Uri ng Sakit: Pananaliksik sa Kanser sa Suso

Mga Kinakailangan sa Kwalipikasyon:

-Locally advanced (inoperable) or metastatic triple negative breast cancer that is PD-L1 positive with measurable disease
-Must have completed treatment for stage I-III as indicated with 6 ≥ months between finishing treatment with curative intent and documented disease recurrence, de novo metastatic triple negative breast cancer allowed
-No: previous treatment for advanced disease; prior therapy with agent directed to another stimulatory or coinhibitory T Cell receptor (CTLA-4, OX-40, CD137);
received systemic anticancer treatment within past 6 months or radiation treatment within last 2 weeks; received topoisomerase 1 inhibitors or antibody drug conjugates
containing isomerase inhibitor; HIV positive patients with history of Kaposi’s sarcoma and/or multicentric Castleman’s disease; active Hep B or Hep C infection; autoimmune disease requiring 
systemic treatment within past 2 years; have known active central nervous system metastasis or carcinomatous meningitis; allogenic tissue or solid organ transplant; myocardial infarction or unstable angina pectoris within last 6 months, history of ventricular arrhythmia or high grade atrioventricular block or other cardiac arrhythmias requiring antiarrhythmic medication, New York Heart Association Grade III or IV heart failure or ejection fraction < 40%, history of QT interval prolongation; have active chronic inflammatory bowel disease (ulcerative colitis or Crohn’s) or GI perforation in last 6 months; history of or active non-infectious pneumonitis or interstitial lung disease, history of active tuberculosis. 

Available sa: